SFTPD and bronchopulmonary dysplasia: Several therapeutic strategies targeting inflammation are currently under clinical development to reduce BPD (39), including anakinra (IL-1 receptor antagonist) (40) and the recombinant human surfactant protein D, an anti-inflammatory collecting protein (41).